GlassScriptPhysician profile
Roger Shih
NPI 1700081577
$1,911.09
in general payments reported to CMS, 2019-2025
30 companies · $37.74 in 2025
The $37.74 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.82 · 2020: $76.32 · 2022: $1,168 · 2023: $543 · 2024: $31.30 · 2025: $37.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $593 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $592.76 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $395.32 | 2022-2023 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $274.42 | 2022-2023 | Trulicity, Mounjaro, Jardiance |
| Amgen INC. | $122.98 | 2022-2025 | Evenity, Repatha |
| Astrazeneca Pharmaceuticals LP | $107.56 | 2020-2023 | Fasenra, Farxiga |
| Merck Sharp & Dohme LLC | $101.77 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.84 | 2022-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.28 | 2022-2023 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $79.62 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $79.48 | 2022-2023 | Rexulti |
| Abbvie INC. | $63.07 | 2022-2024 | Ubrelvy |
| Novartis Pharmaceuticals Corporation | $56.18 | 2022 | |
| Abbott Laboratories | $40.58 | 2022-2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $40.52 | 2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $38.11 | 2022 | |
| Sanofi-Aventis U.S. LLC | $37.59 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $34.33 | 2022-2023 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $27.65 | 2022-2023 | Seglentis |
| Medtronic, INC. | $25.18 | 2022 | |
| Amarin Pharma, INC. | $24.56 | 2022 | |
| Exact Sciences Corporation | $23.42 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $22.31 | 2020 | |
| Dynavax Technologies Corporation | $21.22 | 2023 | Heplisav-B |
| Corcept Therapeutics | $16.88 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.41 | 2022 | |
| Edwards Lifesciences Corporation | $15.38 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Idorsia Pharmaceuticals US INC | $15.35 | 2022 | |
| Endo Pharmaceuticals INC. | $15.18 | 2022 | |
| Portola Pharmaceuticals, LLC | $13.07 | 2020 | |
| Nabriva Therapeutics, Plc | $13.02 | 2022 | |
| Glaxosmithkline, LLC. | $12.81 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Shih listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.